← Back to Search

Monoclonal Antibodies

Elranatamab vs Lenalidomide for Multiple Myeloma (MagnetisMM-7 Trial)

Phase 3

Recruiting

Research Sponsored by Pfizer

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

ECOG performance status ≤1

Diagnosis of MM as defined according to IMWG criteria (Rajkumar, 2014) with measurable disease at diagnosis

Timeline

Screening 3 weeks

Treatment Varies

Follow Up assessed for up to approximately 5 years

Awards & highlights

MagnetisMM-7 Trial Summary

This trial will compare elranatamab to lenalidomide to see if it can provide clinical benefit to those with newly diagnosed multiple myeloma who are MRD-positive.

Who is the study for?

This trial is for individuals with newly diagnosed multiple myeloma who've had a stem cell transplant. They should have responded to initial treatment, be within specific time frames post-transplant, and agree to use contraception. Excluded are those with certain other diseases, previous BCMA therapy, uncontrolled infections or recent investigational drug use.Check my eligibility

What is being tested?

The study compares elranatamab (injected under the skin) against lenalidomide (oral pill) in patients after stem cell transplant for multiple myeloma. The goal is to see if elranatamab can outperform lenalidomide in clinical benefits over approximately five years of participation.See study design

What are the potential side effects?

While not specified here, common side effects of cancer treatments like Elranatamab and Lenalidomide may include fatigue, digestive issues, blood clots, risk of infection and possibly nerve damage. Each patient's experience may vary.

MagnetisMM-7 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am fully active and can carry on all my pre-disease activities without restriction.

Select...

I have been diagnosed with multiple myeloma with measurable disease.

MagnetisMM-7 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ assessed for up to approximately 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~assessed for up to approximately 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and assessed for up to approximately 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Secondary outcome measures

Complete response rate

Duration of complete response

Duration of minimal residual disease negativity

+14 more

MagnetisMM-7 Trial Design

4Treatment groups

Experimental Treatment

Active Control

Group I: Arm C - Part 2Experimental Treatment1 Intervention

Elranatamab

Group II: Arm A - Part 1Experimental Treatment1 Intervention

Elranatamab

Group III: Arm B - Part 1Active Control1 Intervention

Lenalidomide

Group IV: Arm B - Part 2Active Control1 Intervention

Lenalidomide

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Elranatamab

2022

N/A

~10

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor

4,570 Previous Clinical Trials

10,909,680 Total Patients Enrolled

35 Trials studying Multiple Myeloma

8,623 Patients Enrolled for Multiple Myeloma

Pfizer CT.gov Call CenterStudy DirectorPfizer

3,475 Previous Clinical Trials

8,090,794 Total Patients Enrolled

25 Trials studying Multiple Myeloma

3,933 Patients Enrolled for Multiple Myeloma

Media Library

Multiple Myeloma Clinical Trial 2023: Elranatamab Highlights & Side Effects. Trial Name: NCT05317416 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many different geographical areas are part of this research project?

"There are 6 enrolling patients for this study such as Princess Margaret Cancer Centre in Toronto, Centre Integre Universitaire de la Santé et de Services Sociaux de l'Est-de-l'ile-de-Montreal, in Montreal, and Tom Baker Cancer Centre in Calgary,to name a few 6 other locations."

Answered by AI

How many test subjects are being given the opportunity to participate in this trial?

"As many as 366 patients who meet the clinical trial's inclusion criteria are needed to carry out the study. The sponsor, Pfizer, will be running the trial from multiple locations including Princess Margaret Cancer Centre in Toronto, Quebec and Centre Integre Universitaire de la Santé et de Services Sociaux de l'Est-de-l'ile-de-Montreal, in Montreal, Alberta."

Answered by AI

Has Elranatamab undergone the necessary regulatory measures for public consumption?

"Elranatamab is estimated to be a safe medication because it is currently in Phase 3 clinical trials. This means that, while there is still some testing to be done, there is data supporting its efficacy and safety."

Answered by AI

Are there any available openings for patients who want to enroll in this clinical trial?

"The clinical trial is currently recruiting patients, with the most recent update on clinicaltrials.gov being from October 19th, 2022. The trial was originally posted on March 25th, 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

2022. "Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05317416.